Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

inovio pharmaceuticals - INO

INO

Close Chg Chg %
4.35 -0.16 -3.56%

Open Market

4.20

-0.16 (3.56%)

Volume: 341.00K

Last Updated:

Dec 3, 2024, 12:57 PM EDT

Trade Now

Company Overview: inovio pharmaceuticals - INO

INO Key Data

Open

$4.38

 Day Range

4.19 - 4.61

52 Week Range

3.85 - 14.75

 Market Cap

$113.54M

Shares Outstanding

26.10M

 Public Float

25.80M

Beta

0.75

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.48

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

424.52K

  

INO Performance

1 Week
 
 0.69%
 
1 Month
 
 -20.18%
 
3 Months
 
 -30.73%
 
1 Year
 
 -8.92%
 
5 Years
 
 -84.80%
 

INO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About inovio pharmaceuticals - INO

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

INO At a Glance

Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Plymouth Meeting, Pennsylvania 19462-1111
Phone 1-267-440-4200 Revenue 832.01K
Industry Pharmaceuticals: Major Net Income -135,117,352.00
Sector Health Technology Employees 122
Fiscal Year-end 12 / 2024
View SEC Filings

INO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 163.103
Price to Book Ratio 1.189
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.157
Enterprise Value to Sales 24.782
Total Debt to Enterprise Value 1.465

INO Efficiency

Revenue/Employee 6,819.754
Income Per Employee -1,107,519.279
Receivables Turnover 0.346
Total Asset Turnover 0.003

INO Liquidity

Current Ratio 3.597
Quick Ratio 3.597
Cash Ratio 3.413

INO Profitability

Gross Margin -321.093
Operating Margin -16,253.009
Pretax Margin -16,239.871
Net Margin -16,239.871
Return on Assets -51.592
Return on Equity -79.548
Return on Total Capital -91.569
Return on Invested Capital -71.112

INO Capital Structure

Total Debt to Total Equity 25.743
Total Debt to Total Capital 20.473
Total Debt to Total Assets 17.468
Long-Term Debt to Equity 9.401
Long-Term Debt to Total Capital 7.476
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Inovio Pharmaceuticals - INO

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
7.41M 1.77M 10.26M 832.01K
Sales Growth
+80.24% -76.05% +478.23% -91.89%
Cost of Goods Sold (COGS) incl D&A
- 4.73M 5.50M 3.50M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.63M 4.73M 5.50M 3.50M
Depreciation
4.08M 4.21M 5.00M 3.36M
Amortization of Intangibles
547.08K 520.41K 496.49K 145.42K
COGS Growth
- - +16.18% -36.25%
-
Gross Income
- (2.96M) 4.77M (2.67M)
Gross Income Growth
- - +261.24% -156.05%
-
Gross Profit Margin
- -166.56% +46.44% -321.09%
2020 2021 2022 2023 5-year trend
SG&A Expense
133.27M 308.26M 279.04M 132.56M
Research & Development
100.65M 259.24M 194.35M 88.48M
Other SG&A
32.62M 49.02M 84.69M 44.08M
SGA Growth
+14.88% +131.31% -9.48% -52.50%
Other Operating Expense
- - - -
-
Unusual Expense
73.39M 3.22M 7.85M 4.66M
EBIT after Unusual Expense
(203.87M) (314.44M) (282.12M) (139.89M)
Non Operating Income/Expense
49.68M 13.15M 5.72M 5.99M
Non-Operating Interest Income
3.31M 3.36M 4.78M 8.13M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
8.70M 1.94M 1.25M 1.22M
Interest Expense Growth
+9.48% -77.75% -35.24% -2.49%
Gross Interest Expense
8.70M 1.94M 1.25M 1.22M
Interest Capitalized
- - - -
-
Pretax Income
(162.89M) (303.22M) (277.65M) (135.12M)
Pretax Income Growth
-34.83% -86.15% +8.43% +51.34%
Pretax Margin
-2,197.89% -17,085.39% -2,705.57% -16,239.87%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(167.47M) (303.66M) (279.82M) (135.12M)
Minority Interest Expense
- - - (1.06M)
-
Net Income
(166.41M) (303.66M) (279.82M) (135.12M)
Net Income Growth
-39.42% -82.47% +7.85% +51.71%
Net Margin Growth
-2,245.39% -17,109.87% -2,726.67% -16,239.87%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(166.41M) (303.66M) (279.82M) (135.12M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(166.41M) (303.66M) (279.82M) (135.12M)
EPS (Basic)
-12.8729 -17.4492 -14.0717 -6.0936
EPS (Basic) Growth
+11.28% -35.55% +19.36% +56.70%
Basic Shares Outstanding
12.93M 17.40M 19.89M 22.17M
EPS (Diluted)
-12.8729 -17.4492 -14.0717 -6.0936
EPS (Diluted) Growth
+11.28% -35.55% +19.36% +56.70%
Diluted Shares Outstanding
12.93M 17.40M 19.89M 22.17M
EBITDA
(125.85M) (306.49M) (268.78M) (131.72M)
EBITDA Growth
-12.48% -143.53% +12.30% +50.99%
EBITDA Margin
-1,698.16% -17,269.24% -2,619.08% -15,831.92%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 16.50
Number of Ratings 6 Current Quarters Estimate -0.917
FY Report Date 12 / 2024 Current Year's Estimate -4.36
Last Quarter’s Earnings -0.89 Median PE on CY Estimate N/A
Year Ago Earnings -6.09 Next Fiscal Year Estimate -3.455
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 1 6 6
Mean Estimate -0.92 -1.08 -4.36 -3.46
High Estimates -0.77 -1.08 -4.09 -2.05
Low Estimate -1.04 -1.08 -4.71 -4.78
Coefficient of Variance -11.60 N/A -5.23 -33.36

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Inovio Pharmaceuticals - INO

Date Name Shares Transaction Value
May 23, 2024 Simon X. Benito Director 2,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Roger D. Dansey Director 2,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Ann Calby Miller Director 2,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 David B. Weiner Director 2,917 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 David B. Weiner Director 2,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Roger D. Dansey Director 2,917 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Ann Calby Miller Director 2,917 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Wendy L. Yarno Director 2,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Wendy L. Yarno Director 2,917 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Jay P. Shepard Director 2,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Jay P. Shepard Director 2,917 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Lota S. Zoth Director 2,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Lota S. Zoth Director 2,917 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Simon X. Benito Director 2,917 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 17, 2024 Peter D. Kies CFO 26,929 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 17, 2024 Peter D. Kies CFO 9,542 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 17, 2024 Jacqueline E. Shea Chief Executive Officer; Director 33,647 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.07 per share 439,766.29
May 17, 2024 Jacqueline E. Shea Chief Executive Officer; Director 41,365 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 17, 2024 Laurent M. Humeau Chief Scientific Officer 26,040 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 17, 2024 Michael Sumner Chief Medical Officer 4,770 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Inovio Pharmaceuticals in the News